Abstracts tagged "Cutaneous"

Abstract Number: 1777 • ACR Convergence 2025
Granzyme B as a regulator of interferon alpha production in cutaneous lupus erythematosus
Touraj Khosravi¹, Ahmed Eldaboush², Darae Kang³ and Victoria Werth², ¹Department of Dermatology, Perelman Shool of Medicine, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Potomac, MD
Background/Purpose: Recent studies have shown that monocytes, macrophages, and conventional DCs, but not plasmacytoid dendritic cells (pDC), are major sources of IFNα in cutaneous lupus…
Abstract Number: 1758 • ACR Convergence 2025
Treg need a MAIT: Investigating the contribution of MAIT cells to impaired UV-induced Treg expansion in lupus photosensitive reactions
Grace Crossland¹, Lindsay Mendyka¹, Vianey Chavez¹, Kaitlyn Dowling¹, Michael Constantinides² and Sladjana Skopelja-Gardner¹, ¹Dartmouth College, Lebanon, NH, ²Scripps, La Jolla
Background/Purpose: Most systemic lupus erythematosus (SLE) patients experience sensitivity to ultraviolet (UV) light, which can trigger disfiguring skin lesions or systemic flares. In healthy skin,…
Abstract Number: 1720 • ACR Convergence 2025
Comparison of Mortality Trends in Adults with Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus: A 21-Year Analysis Using CDC WONDER DATABASE.
Khadija Mohib¹, Rameez Qasim², Zaiya Waseem³, Shaheer Ahmad⁴ and Ahmad Ali Hussain⁵, ¹Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, ²Allama Iqbal Medical College Lahore, Lahore, Pakistan, ³AtlantiCare Regional Medical Center, New Jersey, ⁴Allama Iqbal Medical College, Lahore, Pakistan, ⁵Allama Iqbal Medical College Lahore, Lahore
Background/Purpose: Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) are chronic autoimmune diseases with significant morbidity and mortality, collectively accounting for approximately 5,000 deaths…
Abstract Number: 1518 • ACR Convergence 2025
Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Ali Ali¹, Neelay Purohit², Ciji Robinson², Amanda Darzi³ and Alireza Meysami⁴, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Canton, MI, ²Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System, Detroit, MI, ³Department of Internal Medicine, Henry Ford Health System, Detroit, MI, ⁴Henry Ford Health, Detroit, MI
Background/Purpose: Anifrolumab, a monoclonal antibody targeting the type I interferon receptor, demonstrated clinical efficacy in systemic lupus erythematosus in the pivotal TULIP-2 trial¹. However, its…
Abstract Number: 1414 • ACR Convergence 2025
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Eugeniu Russu¹, Victor Cazac², Mircea Betiu³, Alesea Nistor³ and Liliana Groppa⁴, ¹"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova, ²Norwalk Hospital, Nuvance Health, Connecticut, ³State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Chisinau, Moldova, ⁴State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops in ~20-30% of psoriasis patients. However, early PsA diagnosis is challenging due to heterogeneous, subtle symptoms and overlap with psoriasis…
Abstract Number: 1152 • ACR Convergence 2025
Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience
Claudia Campos-Fabre¹, Carlota Ureta-Moneva¹, Elena Sendagorta¹, Jose Rodríguez-Gago¹, Maria José Beato¹, Agustin Remesal², Rosa Alcobendas¹, Clara Udaondo¹, Gema Bonilla³, Laura Nuño⁴, Irene Monjo Henry², Carolina Tornero⁵ and Chamaida Plasencia-Rodríguez², ¹La Paz University Hospital, Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ⁴Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁵Hospital La Paz, Madrid, Spain
Background/Purpose: Panniculitis refers to inflammatory disorders of subcutaneous fat that pose diagnostic challenges due to nonspecific clinical features and overlapping histopathological patterns. Although it can…
Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Shady Younis¹, Suman Acharya¹, Gayathri Swaminathan¹, Heidi Wong¹, Hannah Kim¹, Alec Eschholz¹, Subramanya Hegde², Andrew McKnight³, William Robinson⁴ and Lisa Zaba¹, ¹Stanford University, Stanford, CA, ²Sanofi US, New Jersey, MA, ³Sanofi US, Cambridge, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…
Abstract Number: 2370 • ACR Convergence 2024
Redefining Clinical Trial Inclusion Criteria Using Quality of Life in Cutaneous Lupus Erythematosus
Daniella Faden¹, lillian Xie², Caroline Stone¹, Lais Lopes Almeida Gomes¹, Ahmed Eldaboush¹, Cristina Ricco², Rui Feng² and Victoria Werth³, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, ³University of Pennsylvania, Wynnewood, PA
Background/Purpose: Regulatory guidance on endpoint measures for disease activity in cutaneous lupus erythematosus (CLE) patients is essential to improve therapies. CLE profoundly impacts quality of…
Abstract Number: 2385 • ACR Convergence 2024
Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
Anastasia- Bilio Chronopoulou¹, Maria Gerochristou², Sylvia Raftopoulou³, Alexander Stratigos⁴ and Clio Mavragani⁵, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ³Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ⁴1st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disease characterized by a spectrum of cutaneous manifestations resulting from immune dysregulation and inflammation. While…
Abstract Number: 0084 • ACR Convergence 2024
DB-2304, an Immunomodulatory Antibody‒drug Conjugate (ADC) Targeting BDCA2, Displays Strong In Vivo Efficacy in Pharmacodynamic and Psoriasis Models
Xi Li, bing Li, Jun Yao, bin zhang, zhongyuan zhu, yang Qiu and haiqing Hua, Duality Biologics Ltd, Shanghai, China (People's Republic)
Background/Purpose: BDCA2 (blood dendritic cell antigen 2) is specifically expressed on plasmacytoid dendritic cells (pDCs), whose over-production of type I interferon (IFN-I) is crucial in…
Abstract Number: 2403 • ACR Convergence 2024
Health-related Quality of Life in Women with Systemic Lupus Erythematosus with Permanent Skin Damage and Its Association with Self-esteem and Symptoms of Depression and Anxiety – a Cross-sectional Study
Fernando A Oliveira¹, Fabiana Moura², Ana Flávia Dias³, Claudia Santoro³, Fernando Pereira², Rosa Telles² and Cristina Lanna², ¹Faculdade de Ciências Médicas de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ²Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil, ³Grupo Santa Casa de Belo Horizonte, Belo Horizonte, Minas Gerais, Brazil
Background/Purpose: Body image of systemic lupus erythematosus (SLE) patients is affected by the mucocutaneous manifestations and its scars, in particular related to discoid lupus. The…
Abstract Number: 0290 • ACR Convergence 2024
Deucravacitinib Long-term Efficacy Through 4 Years in Week 16 Placebo Crossover Patients in the Phase 3 POETYK PSO-1, PSO-2, and LTE Program
Mark Lebwohl¹, Richard Warren², Shinichi Imafuku³, Jerry Bagel⁴, April W. Armstrong⁵, Thierry Passeron⁶, Subhashis Banerjee⁷, Renata M. Kisa⁸, Matthew J. Colombo⁷, Thomas Scharnitz⁸, Kim Hoyt⁸, Diamant Thaçi⁹ and Andrew Blauvelt¹⁰, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Dermatology Centre, Northern Care Alliance NHS Foundation Trust and NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³Fukuoka University Hospital Faculty of Medicine, Fukuoka, Japan, ⁴Psoriasis Treatment Center of New Jersey, East Windsor, ⁵University of California Los Angeles, Los Angeles, ⁶Université Côte d’Azur, University Hospital of Nice, Nice, France, ⁷Bristol Myers Squibb, Princeton, NJ, ⁸Bristol Myers Squibb, Princeton, ⁹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ¹⁰Oregon Medical Research Center, Portland, OR
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US, EU, and other countries for treatment of adults with moderate…
Abstract Number: 0309 • ACR Convergence 2024
Characteristics and Factors Associated with Treatment Response Among Patients with Eosinophilic Fasciitis: A Systematic Review and Meta-analysis
Omar Hamdan¹, Roa'a Alshajrawi¹, Qais Mussa¹, Yazeed Alajlouni¹, Yazan Dabbah¹, Rawan Fratekh¹, Yousef Al-Mabrouk², Shatha Al-Mabrok² and Ahmad A. Toubasi¹, ¹University of Jordan, Amman, Jordan, ²Mansoura University, Al Mansoura, Egypt
Background/Purpose: To date, data on the clinical features, diagnosis and the treatment of Eosinophilic Fasciitis (EF) patients are mostly derived from individual case reports, with…
Abstract Number: 0314 • ACR Convergence 2024
Microvascular Differences Between Acute and Chronic Cutaneous Graft versus Host Disease
Sehreen Mumtaz¹, Florentina Berianu², Benjamin Wang³, Breanna Cane⁴ and Olayemi Sokumbi⁴, ¹Mayo Clinic, Florida, Jacksonville, FL, ²mayo clinic, Ponte Vedra Beach, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Florida, Jacksonville, FL
Background/Purpose: Cutaneous involvement in systemic sclerosis (SSc) and chronic sclerodermoid graft versus host disease (GVHD) is visibly indistinguishable and while characteristic nailfold videocapillaroscopy (NVC) patterns…
Abstract Number: 0632 • ACR Convergence 2024
Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Tyler Cepica¹, Lillian Xie², Daniella Faden², Caroline Stone³, Victoria Werth⁴ and Benjamin Chong⁵, ¹University of Texas Southwestern Medical School, Benbrook, TX, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Phiiladelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].